New drug duo shows promise for tough bladder cancer
NCT ID NCT03258593
First seen Jan 06, 2026 · Last updated May 25, 2026 · Updated 24 times
Summary
This early-phase study tested two drugs—durvalumab and vicineum—in 15 people with a type of bladder cancer that hadn't spread to the muscle but kept returning after standard treatment. The goal was to see if the combination was safe and could help the immune system attack the cancer. Participants received both drugs for up to 2 years, with regular check-ups and tumor samples.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for URINARY BLADDER NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.